Trial · NCT02855125
Results by group14
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 14 of 14
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Progression-free Survival (PFS) Based on Central Independent Review | TAS-114 + S-1 | 3.65 | 95% Confidence Interval 2.69 to 5.16 | months | |
| Progression-free Survival (PFS) Based on Central Independent Review | S-1 (Monotherapy) | 4.17 | 95% Confidence Interval 2.60 to 6.60 | months | |
| Overall Survival (OS) | TAS-114 + S-1 | 7.92 | 95% Confidence Interval 6.28 to 10.78 | months | |
| Overall Survival (OS) | S-1 (Monotherapy) | 9.82 | 95% Confidence Interval 7.66 to 13.40 | months | |
| Overall Response Rate (ORR) Based on Central Independent Review | TAS-114 + S-1 | 19.7 | 95% Confidence Interval 10.6 to 31.8 | percentage of participants | |
| Overall Response Rate (ORR) Based on Central Independent Review | S-1 (Monotherapy) | 10.3 | 95% Confidence Interval 3.9 to 21.2 | percentage of participants | |
| Disease Control Rate (DCR) Based on Central Independent Review | TAS-114 + S-1 | 80.3 | 95% Confidence Interval 68.2 to 89.4 | percentage of participants | |
| Disease Control Rate (DCR) Based on Central Independent Review | S-1 (Monotherapy) | 75.9 | 95% Confidence Interval 62.8 to 86.1 | percentage of participants | |
| Duration of Response (DR) Based on Central Independent Review | TAS-114 + S-1 | 3.38 | 95% Confidence Interval 2.37 to 4.86 | months | |
| Duration of Response (DR) Based on Central Independent Review | S-1 (Monotherapy) | NA | 95% Confidence Interval 2.79 to NA | months | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) | TAS-114 + S-1 | Participants with TEAEs | 64 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) | S-1 (Monotherapy) | Participants with TEAEs | 61 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) | TAS-114 + S-1 | Participants with TESAEs | 30 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) | S-1 (Monotherapy) | Participants with TESAEs | 19 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02855125/results